Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.22 and traded as low as $0.1411. Northwest Biotherapeutics shares last traded at $0.1535, with a volume of 11,162,504 shares.
Northwest Biotherapeutics Price Performance
The stock has a market capitalization of $259.08 million, a P/E ratio of -0.01 and a beta of -0.63. The company has a fifty day moving average of $0.21 and a two-hundred day moving average of $0.22.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Further Reading
- Five stocks we like better than Northwest Biotherapeutics
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
